Carlos S. Moreno, Ph.D.

Assistant Professor Department of Pathology & Laboratory Medicine Emory University School of Medicine Department of Hematology & Oncology Winship Cancer Institute MORENO LAB HOMEPAGE

RESEARCH INTERESTS:

My laboratory is using DNA microarrays to identify novel targets for cancer therapy in patient tissues from prostate, brain, and ovarian cancers. We are also using model cell culture systems with defined sets of oncogenes to attempt to understand the changes in gene expression that are essential for tumor formation. We are also developing novel bioinformatics techniques to integrate microarray and genomic data and identify functional cis-regulatory DNA elements. Finally, we are using feedback control systems modeling approaches to build new tools for understanding gene transcription regulatory networks.

EDUCATION:

Emory University                Atlanta, GA
                     Ph.D. in Genetics and Molecular Biology (1992-98)

Massachusetts Institute Of Technology                       Cambridge, MA
                     M.S. in Aerospace Engineering (1986-88)

Massachusetts Institute Of Technology                       Cambridge, MA
                     B.S. in Aerospace Engineering (1982-86)

POSTGRADUATE TRAINING:

1998-2001  Postdoctoral Fellow in the laboratory of Dr. David C. Pallas, Biochemistry Department, Emory University School of Medicine.  Identified and analyzed the striatin/SG2NA family of regulatory subunits for Protein Phosphatase 2A (PP2A) and their role in cell cycle regulation.  Discovered that the mouse homolog of MOB1, a yeast protein essential for initiation of cytokinesis and maintenance of ploidy, binds to striatin/PP2A and SG2NA/PP2A complexes and is a PP2A substrate.  Developed and applied quality threshold clustering algorithms for analysis of gene expression profiles of renal carcinomas.

GRADUATE TRAINING:

1992-1998  Studied the regulation of transcription of human Major Histocompatibility Complex (MHC) class II genes.  Cloned and characterized factors that bind to the X box of MHC class II promoters.  One of these factors, X2BP, was purified and shown to be identical to the cAMP response element binding protein (CREB).  The other factor, RFX, was shown to be a multimeric phosphoprotein, and a novel subunit (RFX-B) was identified by metabolic labeling and immunoprecipitation analysis.

RESEARCH EXPERIENCE:

1990-1992 Aerospace Engineer, CS Draper Laboratory, Cambridge, MA.  Developed changes to the Space Shuttle Navigation Flight Software for incorporation of Global Positioning System (GPS) navigation data.   Enhanced and developed computer simulations of Space Shuttle Re-Entry.

1988-1990 Aerospace Engineer, NASA Jet Propulsion Laboratory, Pasadena, CA. Performed technology development research for the Mars Rover/Pathfinder Mission.  Researched remote sample acquisition, robotic end effector technology, semi-autonomous navigation systems, and lander/rover vehicle design.

GRANTS:

NIH National Cancer Institute K22 Career Transition Award (2002-05)        "K22 CA 96560-01 Quality Threshold Analysis of Prostate Cancers"

NIH National Cancer Institute R01 (2005-09) "R01 CA106826 Developmental Transcription Factors in Prostate Cancer"

PUBLICATIONS:

2008. CD McCabe, DD Spyropoulos, WD Martin, and CS Moreno. Genome-wide Analysis of the Homeobox C6 Transcriptional Network in Prostate Cancer, Cancer Research, 68(6): 1988-96.

2008. CO Evans, CS Moreno, X Zhan, M McCabe, PM Vertino, DM Desiderio, and NM Oyesiku. Molecular Signaling in Human Prolactin-Secreting Adenomas Identified by Gene Expression Profiling, RT-qPCR, and Proteomic Analyses, Pituitary, Jan 9, Epub ahead of print.

2008. M. Abramovitz, M. Ordanic-Kodani, Y. Wang, Z. Li, C. Catzavelos, M. Bouzyk, G. W. Sledge Jr, C.S. Moreno, and B. Leyland-Jones. Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay. Biotechniques, 44(3): 417-23.

2007. C.S. Moreno, L. Matyunina, E. Dickerson, N. Schubert, N.J. Bowen, S. Logani, B.B. Benigno and J.F. McDonald, Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas, PLoS ONE, 2(5): e441.

2007. DL Jaye, N Fujita, CM Geigerman, RE Fuller, S Li, S Hunter, P Taysavang, CS Moreno, and PA Wade. The BCL-6-associated transcriptional corepressor, MTA3, is selectively expressed in germinal center B cells and lymphomas of putative germinal center derivation, Journal of Pathology, 213(1):106-15.

2006. P. Liu, S. Ramachandran, M. Ali-Seyed, C.D. Scharer, N. Laycock, W. B. Dalton, H. Williams, S. Karanam, M. W. Datta, D. L. Jaye, and C. S. Moreno. SOX4 is a Transforming Oncogene in Human Prostate Cancer Cells. Cancer Research, 66(8):4011-4018.

2006. Ali-Seyed M, Laycock N, Karanam S, Xiao W, Blair ET, and C. S. Moreno. Cross-Platform Expression Profiling Demonstrates that SV40 Small Tumor Antigen Activates Notch, Hedgehog, and Wnt Signaling in Human Cells. BMC Cancer, 6:54.

2005. C. S. Moreno, C.O. Evans, X. Zhan, M. Okor, D. M. Desiderio, and N.M. Oyesiku, Novel Molecular Signaling in Human Clinically Non-functional Pituitary Adenomas Identified by Gene Expression Profiling and Proteomic Analyses, Cancer Research, 65(22):10214-10222.

2005. A. Schuetz, M. B. Amin, C. S. Moreno, Q. Yin-Goen, C. Cohen, C. D. Hornsby, J. A. Petros, M. M. Issa, J. G. Pattaras, K. Ogan, F. F. Marshall and A. N. Young. Molecular Classification of Renal Tumors by Gene Expression Profiling. Journal of Molecular Diagnostics, 7(2):206-18.

2005. S. Ramachandran, P. Liu, A. N. Young, Q. Yin-Goen, S. D. Lim, N. Laycock, M. B. Amin, J. K. Carney, F. F. Marshall, J. A. Petros and C. S. Moreno. Loss of HOXC6 Expression Induces Apoptosis in Prostate Cancer Cells. Oncogene, 24(1): 188-198.

2004. C. S. Moreno, S. Ramachandran, D. Ashby, N. Laycock, C. A. Plattner, W. Chen, W. C. Hahn and D. C. Pallas. Signaling and Transcriptional Changes Critical for Transformation of Human Cells by SV40 Small Tumor Antigen or PP2A B56gamma Knockdown. Cancer Res, 64: 6978-6988.

2004. S. Karanam and C. S. Moreno. CONFAC: Automated Application of Comparative Genomic Promoter Analysis to DNA Microarray Datasets. Nucleic Acids Res, 32: W475-84.

2003. N. Fujita, D. L. Jaye, M. Kajita, C. Geigerman, C. S. Moreno and P. A. Wade. MTA3, a Mi-2/NuRD Complex Subunit, Regulates an Invasive Growth Pathway in Breast Cancer. Cell, 113: 207-19.

2002. S. B. Hunter and C. S. Moreno. Expression microarray analysis of brain tumors: what have we learned so far. Front Biosci, 7: c74-82.

2001. X. X. Yu, X. Du, C. S. Moreno, R. E. Green, E. Ogris, Q. Feng, L. Chou, M. J. McQuoid and D. C. Pallas. Methylation of the Protein Phosphatase 2A Catalytic Subunit Is Essential for Association of Balpha Regulatory Subunit But Not SG2NA, Striatin, or Polyomavirus Middle Tumor Antigen. Mol Biol Cell, 12: 185-99.

2001. A. N. Young, M. B. Amin, C. S. Moreno, S. D. Lim, C. Cohen, J. A. Petros, F. F. Marshall and A. S. Neish. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol, 158: 1639-51.

2001. H. Wei, D. G. Ashby, C. S. Moreno, E. Ogris, F. M. Yeong, A. H. Corbett and D. C. Pallas. Carboxymethylation of the PP2A catalytic subunit in Saccharomyces cerevisiae is required for efficient interaction with the B-type subunits Cdc55p and Rts1p. J Biol Chem, 276: 1570-7.

2001. C. S. Moreno, W. S. Lane and D. C. Pallas. A mammalian homolog of yeast mob1 is both a member and a putative substrate of striatin family-protein phosphatase 2a complexes. J Biol Chem, 276: 24253-60.

2000. C. S. Moreno, S. Park, K. Nelson, D. Ashby, F. Hubalek, W. S. Lane and D. C. Pallas. WD40 repeat proteins striatin and S/G(2) nuclear autoantigen are members of a novel family of calmodulin-binding proteins that associate with protein phosphatase 2A. J Biol Chem, 275: 5257-63.

1999. C. S. Moreno, G. W. Beresford, P. Louis-Plence, A. C. Morris and J. M. Boss. CREB regulates MHC class II expression in a CIITA-dependent manner. Immunity, 10: 143-51.

1997. C. S. Moreno, E. M. Rogers, J. A. Brown and J. M. Boss. Regulatory factor X, a bare lymphocyte syndrome transcription factor, is a multimeric phosphoprotein complex. J Immunol, 158: 5841-8.

1997. P. Louis-Plence, C. S. Moreno and J. M. Boss. Formation of a regulatory factor X/X2 box-binding protein/nuclear factor-Y multiprotein complex on the conserved regulatory regions of HLA class II genes. J Immunol, 159: 3899-909.

1995. C. S. Moreno, P. Emery, J. E. West, B. Durand, W. Reith, B. Mach and J. M. Boss. Purified X2 binding protein (X2BP) cooperatively binds the class II MHC X box region in the presence of purified RFX, the X box factor deficient in the bare lymphocyte syndrome. J Immunol, 155: 4313-21.

1994. K. C. Chin, C. Mao, C. Skinner, J. L. Riley, K. L. Wright, C. S. Moreno, G. R. Stark, J. M. Boss and J. P. Ting. Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction. Immunity, 1: 687-97.

MORENO LAB HOMEPAGE

ADDRESS:	Department of Pathology & Laboratory Medicine Emory University School of Medicine Whitehead Research Building, Room 105J 615 Michael St. Atlanta, GA 30322	PHONE:	404-712-2809 (office) 404-712-2808 (lab)
email:	cmoreno@emory.edu	FAX:	404-727-8538